{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:55:06Z","timestamp":1789772106301,"version":"4.0.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ajo.2026.02.030","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T07:37:11Z","timestamp":1771918631000},"page":"108-122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Association Between Retinal Vein Occlusion and Epiretinal Membrane Development"],"prefix":"10.1016","volume":"286","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9867-027X","authenticated-orcid":false,"given":"Abdulkader","family":"Almosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Alshaikhsalama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5216-639X","authenticated-orcid":false,"given":"Ahmed","family":"Abdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2492-1993","authenticated-orcid":false,"given":"Amer F.","family":"Alsoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5097-110X","authenticated-orcid":false,"given":"Melissa","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asad","family":"Loya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Rahimy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9792-4159","authenticated-orcid":false,"given":"Tamer H.","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ajo.2026.02.030_bib0001","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.ophtha.2010.08.009","article-title":"Prevalence and risk factors for epiretinal membranes in a multi-ethnic United States population","volume":"118","author":"Ng","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2026.02.030_bib0002","doi-asserted-by":"crossref","unstructured":"Xiao W., Chen X., Yan W., Zhu Z., He M. Prevalence and risk factors of epiretinal membranes: a systematic review and meta-analysis of population-based studies. BMJ Open. 2017;7(9):e014644. doi:10.1136\/bmjopen-2016-014644","DOI":"10.1136\/bmjopen-2016-014644"},{"issue":"3","key":"10.1016\/j.ajo.2026.02.030_bib0003","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s10384-018-0581-x","article-title":"Comparison of visual acuity, metamorphopsia, and aniseikonia in patients with an idiopathic epiretinal membrane","volume":"62","author":"Tanikawa","year":"2018","journal-title":"Jpn J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2026.02.030_bib0004","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41433-021-01681-0","article-title":"Idiopathic epiretinal membrane: progression and timing of surgery","volume":"36","author":"Chua","year":"2022","journal-title":"Eye"},{"issue":"3","key":"10.1016\/j.ajo.2026.02.030_bib0005","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/ceo.13914","article-title":"Epiretinal membrane: a review","volume":"49","author":"Fung","year":"2021","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.ajo.2026.02.030_bib0006","article-title":"Pathophysiology and clinical aspects of epiretinal membrane - review","volume":"10","author":"O\u017c\u00f3g","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"10.1016\/j.ajo.2026.02.030_bib0007","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.3390\/ijms22042179","article-title":"VEGF-independent activation of M\u00fcller cells by the vitreous from proliferative diabetic retinopathy patients","volume":"22","author":"Rezzola","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.ajo.2026.02.030_bib0008","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s40123-022-00461-7","article-title":"Epiretinal membrane peeling in eyes with retinal vein occlusion: visual and morphologic outcomes","volume":"11","author":"Cicinelli","year":"2022","journal-title":"Ophthalmol Ther"},{"issue":"3","key":"10.1016\/j.ajo.2026.02.030_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2025.100733","article-title":"Epiretinal membrane is associated with diabetic retinopathy severity and cumulative anti-VEGF injections","volume":"5","author":"Kakihara","year":"2025","journal-title":"Ophthalmol Sci"},{"issue":"3","key":"10.1016\/j.ajo.2026.02.030_bib0010","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1136\/bjo.2009.177287","article-title":"Intravitreal bevacizumab for retinal vein occlusion and early growth of epiretinal membrane: a possible secondary effect?","volume":"95","author":"Marticorena","year":"2011","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2026.02.030_bib0011","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00417-014-2731-2","article-title":"Visual outcome and prognostic factors after surgery for a secondary epiretinal membrane associated with branch retinal vein occlusion","volume":"253","author":"Kang","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"issue":"6","key":"10.1016\/j.ajo.2026.02.030_bib0012","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0161-6420(97)30190-0","article-title":"Prevalence and associations of epiretinal membranes. The Blue Mountains Eye Study, Australia","volume":"104","author":"Mitchell","year":"1997","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.ajo.2026.02.030_bib0013","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1371\/journal.pmed.0040297","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration","volume":"4","author":"Vandenbroucke","year":"2007","journal-title":"PLoS Med."},{"issue":"8","key":"10.1016\/j.ajo.2026.02.030_bib0014","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/eye.2011.92","article-title":"The burden of disease of retinal vein occlusion: review of the literature","volume":"25","author":"Laouri","year":"2011","journal-title":"Eye (Lond)"},{"issue":"1","key":"10.1016\/j.ajo.2026.02.030_bib0015","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s12886-021-01944-0","article-title":"Epiretinal membrane appearance or progression after intravitreal injection in age-related macular degeneration","volume":"21","author":"Taniguchi","year":"2021","journal-title":"BMC Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajo.2026.02.030_bib0016","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ajo.2005.03.003","article-title":"Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6","volume":"140","author":"Noma","year":"2005","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2026.02.030_bib0017","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s11481-014-9531-7","article-title":"Vascular endothelial growth factor signaling in hypoxia and inflammation","volume":"9","author":"Ramakrishnan","year":"2014","journal-title":"J Neuroimmune Pharmacol."},{"issue":"12","key":"10.1016\/j.ajo.2026.02.030_bib0018","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1001\/archopht.1995.01100120068012","article-title":"Hypoxic regulation of vascular endothelial growth factor in retinal cells","volume":"113","author":"Aiello","year":"1995","journal-title":"Arch Ophthalmol."},{"issue":"2","key":"10.1016\/j.ajo.2026.02.030_bib0019","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.preteyeres.2005.09.001","article-title":"The role of cytokines and trophic factors in epiretinal membranes: involvement of signal transduction in glial cells","volume":"25","author":"Harada","year":"2006","journal-title":"Prog Retin Eye Res."},{"issue":"1","key":"10.1016\/j.ajo.2026.02.030_bib0020","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2018-000249","article-title":"Five-year outcomes of retinal vein occlusion treated with vascular endothelial growth factor inhibitors","volume":"4","author":"Spooner","year":"2019","journal-title":"BMJ Open Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajo.2026.02.030_bib0021","first-page":"1450","article-title":"Decreased nitric oxide production accounts for secondary arteriolar constriction after retinal branch vein occlusion","volume":"38","author":"Donati","year":"1997","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"10.1016\/j.ajo.2026.02.030_bib0022","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1136\/bjophthalmol-2015-308199","article-title":"The relationship between anti-vascular endothelial growth factor and fibrosis in proliferative retinopathy: clinical and laboratory evidence","volume":"100","author":"Zhang","year":"2016","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2026.02.030_bib0023","first-page":"H1054","article-title":"VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells","volume":"274","author":"Hood","year":"1998","journal-title":"Am J Physiol."},{"issue":"8","key":"10.1016\/j.ajo.2026.02.030_bib0024","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/j.1755-3768.2008.01175.x","article-title":"Ischaemic change after intravitreal bevacizumab (avastin) injection for macular oedema secondary to non-ischaemic central retinal vein occlusion","volume":"86","author":"Kim","year":"2008","journal-title":"Acta Ophthalmol."},{"issue":"Pt 9","key":"10.1016\/j.ajo.2026.02.030_bib0025","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1242\/jcs.107.9.2459","article-title":"Platelet-derived growth factor is an autocrine growth stimulator in retinal pigmented epithelial cells","volume":"107","author":"Campochiaro","year":"1994","journal-title":"J Cell Sci."},{"issue":"10","key":"10.1016\/j.ajo.2026.02.030_bib0026","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1136\/bjo.81.10.919","article-title":"Localisation of vascular endothelial growth factor and its receptors to cells of vascular and avascular epiretinal membranes","volume":"81","author":"Chen","year":"1997","journal-title":"Br J Ophthalmol."},{"issue":"9","key":"10.1016\/j.ajo.2026.02.030_bib0027","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1001\/archophthalmol.2009.234","volume":"127","author":"Ip","year":"2009","journal-title":"Arch Ophthalmol."},{"issue":"1","key":"10.1016\/j.ajo.2026.02.030_bib0028","doi-asserted-by":"crossref","first-page":"8484","DOI":"10.1038\/s41598-024-57798-1","article-title":"Interpretable detection of epiretinal membrane from optical coherence tomography with deep neural networks","volume":"14","author":"Ayhan","year":"2024","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.ajo.2026.02.030_bib0029","article-title":"Surgery for idiopathic epiretinal membrane","volume":"3","author":"Yusuf","year":"2021","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.ajo.2026.02.030_bib0030","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/989501","article-title":"Intravitreal steroids for the treatment of retinal diseases","volume":"2014","author":"Sarao","year":"2014","journal-title":"ScientificWorldJournal"},{"issue":"1","key":"10.1016\/j.ajo.2026.02.030_bib0031","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0002-9394(80)90239-1","article-title":"Inhibition of intraocular proliferations with intravitreal corticosteroids","volume":"89","author":"Tano","year":"1980","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2026.02.030_bib0032","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.oret.2021.05.004","article-title":"Age, gender, and laterality of retinal vascular occlusion: a retrospective study from the IRIS\u00ae registry","volume":"6","author":"Li","year":"2022","journal-title":"Ophthalmol Retina"},{"issue":"10","key":"10.1016\/j.ajo.2026.02.030_bib0033","doi-asserted-by":"crossref","DOI":"10.1115\/1.4043832","article-title":"Embolus analog trajectory paths under physiological flowrates through patient-specific aortic arch models","volume":"141","author":"Malone","year":"2019","journal-title":"J Biomech Eng"},{"issue":"4","key":"10.1016\/j.ajo.2026.02.030_bib0034","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.oret.2022.11.001","article-title":"Central retinal vein occlusion 36-month outcomes with anti-VEGF: the fight retinal blindness! registry","volume":"7","author":"Hunt","year":"2023","journal-title":"Ophthalmol Retina."},{"issue":"1","key":"10.1016\/j.ajo.2026.02.030_bib0035","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s41598-020-57509-6","article-title":"Incidence and treatment outcomes of secondary epiretinal membrane following intravitreal injection for diabetic macular edema","volume":"10","author":"Kang","year":"2020","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.ajo.2026.02.030_bib0036","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1755-3768.2008.01225.x","article-title":"Progression of tractional retinal detachment following intravitreal bevacizumab","volume":"87","author":"Jonas","year":"2009","journal-title":"Acta Ophthalmol."},{"issue":"6","key":"10.1016\/j.ajo.2026.02.030_bib0037","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.survophthal.2021.03.001","article-title":"Anti-VEGF crunch syndrome in proliferative diabetic retinopathy: a review","volume":"66","author":"Tan","year":"2021","journal-title":"Surv Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2026.02.030_bib0038","doi-asserted-by":"crossref","first-page":"luaf083","DOI":"10.1210\/jcemcr\/luaf083","article-title":"Anti-vascular endothelial growth factor crunch syndrome in proliferative diabetic retinopathy","volume":"3","author":"Li","year":"2025","journal-title":"JCEM Case Rep"},{"issue":"4","key":"10.1016\/j.ajo.2026.02.030_bib0039","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1136\/bjophthalmol-2011-301005","article-title":"A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy","volume":"96","author":"Van Geest","year":"2012","journal-title":"Br J Ophthalmol."},{"issue":"7","key":"10.1016\/j.ajo.2026.02.030_bib0040","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.ophtha.2018.01.004","article-title":"Development and course of scars in the comparison of age-related macular degeneration treatments trials","volume":"125","author":"Daniel","year":"2018","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ajo.2026.02.030_bib0041","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ophtha.2010.02.021","article-title":"Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study","volume":"117","author":"Campochiaro","year":"2010","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ajo.2026.02.030_bib0042","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","article-title":"Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study","volume":"117","author":"Brown","year":"2010","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2026.02.030_bib0043","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.ophtha.2011.12.005","article-title":"Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.ajo.2026.02.030_bib0044","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.ophtha.2014.01.027","article-title":"Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study","volume":"121","author":"Heier","year":"2014","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ajo.2026.02.030_bib0045","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.ajo.2014.07.027","article-title":"Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study","volume":"158","author":"Ogura","year":"2014","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2026.02.030_bib0046","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ophtha.2013.08.038","article-title":"Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study","volume":"121","author":"Campochiaro","year":"2014","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.ajo.2026.02.030_bib0047","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1097\/IAE.0000000000002202","article-title":"Clinical characteristics, long-term surgical outcomes, and prognostic factors of epiretinal membrane in young patients","volume":"39","author":"Chen","year":"2019","journal-title":"Retina"},{"issue":"4","key":"10.1016\/j.ajo.2026.02.030_bib0048","doi-asserted-by":"crossref","first-page":"P197","DOI":"10.1016\/j.ophtha.2024.12.019","article-title":"Idiopathic epiretinal membrane and vitreomacular traction preferred practice pattern","volume":"132","author":"Bailey","year":"2025","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.ajo.2026.02.030_bib0049","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1167\/tvst.13.11.13","article-title":"Ocular pharmacodynamics of intravitreal faricimab in patients with neovascular age-related macular degeneration or diabetic macular edema","volume":"13","author":"Diack","year":"2024","journal-title":"Transl Vis Sci Technol"},{"issue":"11","key":"10.1016\/j.ajo.2026.02.030_bib0050","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1097\/IAE.0000000000004572","article-title":"Impact of faricimab versus aflibercept on epiretinal membrane formation over 2 years in patients with diabetic macular edema in the phase 3 YOSEMITE and RHINE trials","volume":"45","author":"Jaffe","year":"2025","journal-title":"Retina"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426000929?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426000929?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T08:08:41Z","timestamp":1779782921000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939426000929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":50,"alternative-id":["S0002939426000929"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2026.02.030","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association Between Retinal Vein Occlusion and Epiretinal Membrane Development","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2026.02.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}